No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
DNA240517P2000
- 1.15
- 0.000.00%
15min DelayClose May 10 15:59 ET
1.15High1.15Low
1.15Open1.15Pre Close5 Volume5 Open Interest2.00Strike Price575.00Turnover0.00%IV11.71%PremiumMay 17, 2024Expiry Date1.24Intrinsic Value100Multiplier6DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type--Delta--Gamma0.66Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- 1D
News
Ginkgo Bioworks Holdings First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Express News | NYSE Order Imbalance 92611.0 Shares on Buy Side
Ginkgo Bioworks Holdings Inc (DNA) Reports Q1 2024 Results: A Comprehensive Overview
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Diodes Incorporated (NASDAQ:DIOD) fell sharply during Friday's session after the company reported worse-than-expected quarterly financial results.Diodes posted adjusted earnings of 28 cents
Ginkgo Bioworks Holdings Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 — William Blair Downgrades Market Perform → Underperform 03/01/2024 270.37% TD Cowen $7 → $3 M
Express News | Ginkgo Bioworks Holdings Inc : William Blair Cuts to Underperform
Comments
$Ginkgo Bioworks(DNA.US$ no way🥱🦈🦈🦈🦈🦈🦈
$Ginkgo Bioworks(DNA.US$ fell some 10% after hours Thursday after the biotech missed analyst estimates for its Q1 revenue and announced plans to cut $200 million of operating expenses through layoffs and other steps.
DNA sank 10% to $0.83 a share shortly before 5 p.m. ET after the firm said Q1 revenues fell 53% from the same period last year to reach $37.9 million – below the $46.4 million consensus that analysts had reported expected.
Gink...
DNA sank 10% to $0.83 a share shortly before 5 p.m. ET after the firm said Q1 revenues fell 53% from the same period last year to reach $37.9 million – below the $46.4 million consensus that analysts had reported expected.
Gink...
3
2
$Ginkgo Bioworks(DNA.US$Ark invest. just add more $198.6 millions, best for all.
2
4
$Ginkgo Bioworks(DNA.US$ why the hell is it shorting again? the dip buying waa so the obvious move yesterday.
1
Read more